Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

A look at ADAPTIR
July 2017
SHARING OPTIONS:

SEATTLE—The 13th Annual Protein Engineering (PEGS Summit) held this year in Boston saw Aptevo Therapeutics Inc. present details regarding its ADAPTIR protein therapeutic platform. Some of the platform’s advantages noted during the presentation include extended serum half-life of up to 12.5 days in rodents, superior manufacturing attributes of ADAPTIR molecules compared to other bispecific formats, optimized stability of ADAPTIR molecules and potent activity and affinity of ADAPTIR molecules, among others.
 
Dr. Jane Gross, Aptevo’s senior vice president and chief scientific officer, said, “Our ADAPTIR technology is a novel, robust and highly flexible platform with the capability of generating unique monospecific and bispecific therapeutic antibodies with distinct mechanisms of action. Our platform enables tremendous versatility with the ability to engineer multiple different binding domains or ligands onto the ADAPTIR scaffold.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.